Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Bull: Accelerated global adoption of ZYN and continued IQOS momentum lead to margin expansion and faster-than-expected revenue growth.
Global Alternative Ban: Major global markets implement sweeping bans on oral nicotine pouches and heated tobacco, eliminating all key growth vectors.
Philip Morris International is executing a successful transition from combustible tobacco to smoke-free products (IQOS, ZYN), sustaining its mature compounder status through strong pricing power and high ROIC.
Philip Morris International is executing a successful transition from combustible tobacco to smoke-free products (IQOS, ZYN), sustaining its mature compounder status through strong pricing power and high ROIC.
Intangible Assets (Brand Equity)
Cost Advantage (Scale Economies)
Consumers shift rapidly to high-margin reduced-risk products, expanding total market value.
Buy, driven by a durable moat, pricing power, and an increasingly profitable transitioning product portfolio.
Philip Morris International Inc. operates as a tobacco company. The company offers cigarettes and smoke-free products, including heat-not-burn, e-vapor, and oral nicotine products under the IQOS, VEEV, and ZYN brands; and consumer accessories, such as lighters and matches. It also offers wellness products. The company was incorporated in 1987 and is headquartered in Stamford, Connecticut.
Under severe stress, an accelerated decline in traditional combustibles combined with a stalled transition to smoke-free alternatives would heavily compress margins.
Intangible Assets (Brand Equity)
Cost Advantage (Scale Economies)
Economic profit is supported when reported returns exceed the company cost-of-capital hurdle.
Unavailable
FCFF DCF remains positive at the base case: base FCFF $12.9B after capex $1.5B, with terminal value at 73.3% of enterprise value. No FCF cliff is projected unless capex/ or materially resets.
Monitor earnings quality, guidance, and valuation-sensitive operating metrics.
Monitor earnings quality, guidance, and valuation-sensitive operating metrics.
Monitor earnings quality, guidance, and valuation-sensitive operating metrics.
Capex peaks during the initial transition, followed by a high free cash flow yield state.
Consumers shift rapidly to high-margin reduced-risk products, expanding total market value.
Regulatory crackdowns and declining overall global nicotine usage constrain growth.
Capex peaks during the initial transition, followed by a high free cash flow yield state.
Strong Buy. The ongoing transition to high-margin smoke-free products offers an underappreciated growth runway and durable margin expansion.
The market incorrectly prices PM as a structurally declining combustible legacy rather than a transitioning mature compounder.
Buy. The ongoing transition to high-margin smoke-free products offers an underappreciated growth runway and durable margin expansion.
Reassess the thesis against the named valuation, risk, and quarterly checkpoint evidence in this report.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Severe regulatory restrictions on alternative nicotine products in key markets stall growth, while traditional cigarette volumes decline faster than pricing can offset.
Major global markets implement sweeping bans on oral nicotine pouches and heated tobacco, eliminating all key growth vectors.
Combustible cigarette volumes plummet significantly faster than historical averages, destroying base cash flows before the transition matures.
Governments tax reduced-risk products identically to combustibles, completely erasing the margin advantage of the portfolio transition.
The five developments that would weaken our investment case.
Failing to hit smoke-free volume and revenue targets stalls the commercial transition away from combustibles, preventing high-margin reduced-risk product scaling from offsetting traditional volume declines.
Current:7.3% for the period ended 2025-12-31
Alert if< 0.0% over four consecutive quarters
Imposing excise tax parity on smoke-free alternatives eliminates relative consumer price advantages, eroding unit profitability and dismantling the margin expansion thesis underpinning the product transformation.
Current:67.1% for the period ended 2025-12-31
Alert if< 63.3% over two consecutive fiscal years
Loss of combustible pricing leverage prevents the offset of volume contractions, compressing group operating profits and restricting cash flow generation required to fund international expansion.
Current:36.7% for the period ended 2025-12-31
Alert if< 34.7% over four consecutive quarters
Government bans on key pouch and heated tobacco variants eliminate primary growth catalysts, stranding retail inventory, curtailing consumer adoption, and impairing projected earnings streams.
Current:7.26 for the period ended 2025-12-31
Alert ifEnactment of sweeping regulatory bans on flavored oral nicotine or heated tobacco products in major markets
Sub-par returns on capital allocation indicate misallocated manufacturing expenditures and acquisition integration drag, undermining economic value creation and compressing enterprise valuation multiples.
Current:31.5% as of 2026-05-08
Alert if< 25.0% over a 12-month period
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
Project SBC-adjusted EPS, discount each year's earnings at cost of equity, then add a Gordon-growth terminal value.
Project EPS through the explicit advantage period, fade growth as competition catches up, and discount the full stream at cost of equity.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and at , then adjust for signed per current share.
Add depreciation to net income, subtract maintenance capex, divide by diluted shares, and apply a normalized valuation multiple.
Multiply the peer median PEG by this stock's forecast growth to derive an implied forward P/E, then apply it to forward EPS.
Solve for the growth rate that makes the model value equal the report-date share price.
Philip Morris International is executing a successful transition from combustible tobacco to smoke-free products (IQOS, ZYN), sustaining its mature compounder status through strong pricing power and high ROIC.
Monitor earnings quality, guidance, and valuation-sensitive operating metrics.
Warning level: < 0.0% over four consecutive quarters. Failing to hit smoke-free volume and revenue targets stalls the commercial transition away from combustibles, preventing high-margin reduced-risk product scaling from offsetting traditional volume declines.
Warning level: < 63.3% over two consecutive fiscal years. Imposing excise tax parity on smoke-free alternatives eliminates relative consumer price advantages, eroding unit profitability and dismantling the margin expansion thesis underpinning the product transformation.
Warning level: Enactment of sweeping regulatory bans on flavored oral nicotine or heated tobacco products in major markets. Government bans on key pouch and heated tobacco variants eliminate primary growth catalysts, stranding retail inventory, curtailing consumer adoption, and impairing projected earnings streams.
Warning level: < 25.0% over a 12-month period. Sub-par returns on capital allocation indicate misallocated manufacturing expenditures and acquisition integration drag, undermining economic value creation and compressing enterprise valuation multiples.
| — |
| $31.76B |
| $35.17B |
| $37.88B |
| $40.65B |
| +8.6% |
| Gross profit | — | $20.36B | $22.28B | $24.55B | $27.28B | +10.2% |
| Operating income | — | $12.40B | $11.98B | $13.96B | $15.47B | +7.6% |
| Net income | — | $9.05B | $7.81B | $7.06B | $11.35B | +7.8% |
| EPS (diluted) | $5.83 | $5.81 | $5.02 | $4.53 | $7.26 | +5.6% |
| EBITDA | — | $13.48B | $13.37B | $15.75B | $17.46B | +9.0% |
| R&D | — | — | — | — | — | — |
| SG&A | — | $8.11B | $10.06B | $11.15B | $12.35B | +15.0% |
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
| Revenue | 40,648,000,000 |
|---|---|
| Cost of revenue | 13,366,000,000 |
| Gross profit | 27,282,000,000 |
| Operating expenses | 12,349,000,000 |
| Operating income | 14,933,000,000 |
| Non-operating items and tax | -3,585,000,000 |
| Net income | 11,348,000,000 |
Point-in-time financial data used in the 2026-05-08 analysis.
| Period | Revenue | EBITDA | Net income | Operating cash flow | Free cash flow | Capex | Depreciation and amortization | Stock-based compensation | Share repurchases | Dividends paid | Net debt issuance | Investing cash flow | Financing cash flow | Beginning cash | Ending cash | Cash and investments | Total debt | Operating margin | ROIC | WACC | ROIC − WACC spread |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-12-31 | — | — | — | — | — | — | — | — | 775M | — | — | — | — | — | — | — | — | — | — | — | — |
| 2022-12-31 | 31.8B | 13.5B | 9B | 10.8B | 9.7B | 1.1B | 1.1B | — | 209M | 7.8B | 14.2B | — | — | — | — | 3.2B | 43.1B | 38.6% | — | 5.9% | — |
| 2023-12-31 | 35.2B | 13.4B | 7.8B | 9.2B | 7.9B | 1.3B | 1.4B | — | 0 | 8B | 3.7B | — | — | — | — | 3.1B | 47.9B | 34.7% | — | 5.8% | — |
| 2024-12-31 | 37.9B | 15.7B | 7.1B | 12.2B | 10.8B | 1.4B | 1.8B | — | 0 | 8.2B | -1.6B | — | — | — | — | 4.2B | 45.7B | 35.4% | — | 6.4% | — |
| 2025-12-31 | 40.6B | 17.5B | 11.3B | 12.2B | 10.7B | 1.6B | 2B | — | — | 8.6B | 1.7B | — | — | — | — | 4.9B | 48.8B | 36.7% | — | 6.1% | — |
PM trades at 18.7x forward earnings against a peer median of 22.5x; EV/EBITDA of 17.0x against a peer median of 22.2x; 6 peers.
| Walmart Inc. |
| 39.9x |
| 1.5x |
| 25.0x |
| 21.8% |
| 4.6% |
| COST | Costco Wholesale Corporation | 45.0x | 1.6x | 33.2x | 29.7% | 3.7% |
| PG | The Procter & Gamble Company | 20.7x | 3.9x | 14.6x | 31.1% | 23.0% |
| KO | The Coca-Cola Company | 22.5x | 6.8x | 22.2x | 43.4% | 35.1% |
